Antifibrinolytic drugs and perioperative hemostasis

American Journal of Hematology

Volumn 56, Issue 1, 1997, Pages 32-36

  Slaughter, Thomas F ^a,b   Greenberg, Charles S ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Antifibrinolytic drugs; Cardiac surgery; Extracorporeal circulation; Surgical hemostasis

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; TRANEXAMIC ACID;

ANAPHYLAXIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; EXTRACORPOREAL CIRCULATION; FIBRINOLYSIS; HEART SURGERY; HEMOSTASIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; META ANALYSIS; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

ANTIFIBRINOLYTIC AGENTS; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; HEMOSTASIS; HUMANS;

EID: 0030931821     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199709)56:1<32::AID-AJH7>3.0.CO;2-3     Document Type: Article

References (56)

1. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114, 1991.
2. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 326:800, 1992.
3. Tanaka K, Takao M, Yada I, Yuasa H, Kusagaua M, Deguchi K: Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 3:181, 1989.
4. Stibbe J, Kluft C, Brommer EJP, Gomes M, Dejong DS, Nauta J: Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 14:375, 1984.
5. Ranby M: Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 704:461, 1982.
6. Levin EG, Marzec U, Anderson J, Harker LA: Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 74:1988, 1984.
7. Slaughter TF, LeBleu TH, Douglas JM, Leslie JB, Parker JK, Greenberg CS: Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 80:520, 1994.
8. Brister SJ, Ofosu FA, Buchanan MR: Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant? Thromb Haemost 70:259, 1993.
9. Kraut E, Frey EK, Werle E: Uber die Inaktivierung des Kallikreins. Hoppe-Seyler's Z Physiol Chem 192:1, 1930.
10. Okamoto S, Nakajima T, Okamoto U, Watanabe H, Iguchi Y, Igawa T, Ching CC, Hayashi T. A suppressing effect of E-amino caproic acid on the bleeding of dogs produced with the activation of plasmin in the circulatory blood. Keio J Med 8:247, 1959.
11. Okamoto S, Okamoto U: Amino-methyl-cyclohexane-carboxylic acid: AMCHA. A new potent inhibitor of the fibrinolysis. Keio J Med 11:105, 1962.
12. Hoylaerts M, Lijnen HR, Collen D: Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 673:75, 1981.
13. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 29:236, 1985.
14. Andersson L, Nilsson IM, Nilehn JE, Hedner U, Granstrand B, Melander B: Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol 2:230, 1965.
15. Okamoto S, Sato S, Takada Y, Okamoto U: An active stereo isomer (trans form) of AMCHA and its fibrinolytic (antiplasmic) action in vitro and in vivo. Keio Med 13:177, 1964.
16. Del Rossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R: Prophylactic treatment of postperfusion bleeding using EACA. Chest 96:27, 1989.
17. Horrow JC, Hlavacek J, Strong MD, Collier W, Brodsky I, Goldman SM, Goel IP: Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 99:70, 1990.
18. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL: Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 84:2063, 1991.
19. Coffey A, Pittman J, Halbrook H, Fehrenbacher J, Beckman D, Hormuth D: The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: A double-blind randomized trial. Am Surg 61:566, 1995.
20. Rousou JA, Engelman RM, Flack JE, Deaton DW, Owen SG: Tranexamic acid significantly reduces blood loss associated with coronary revascularization. Ann Thorac Surg 59:671, 1995.
21. Vander Salm TJ, Ansell JE, Okike ON, Marsicano TH, Lew R, Stephenson WP, Rooney K: The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: A double-blind randomized study. J Thorac Cardiovasc Surg 95:538, 1988.
22. Ovrum E, Am Holen E, Abdelnoor M, Oystese R, Ringdal ML: Tranexamic acid (cyklokapron) is not necessary to reduce blood loss after coronan artery bypass operations. J Thorac Cardiovasc Surg 105:78, 1993.
23. Fritz H, Wunderer G: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneitmittelforschung 33:479, 1983.
24. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:788, 1990.
25. Van Oeveren W, Jansen NJ, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CR: Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44:640, 1987.
26. Dementieva, Dzemeshkevich SL, Charnaya MA, Shabalkin BV: The use of high doses of aprotinin to decrease blood loss in aortocoronary bypass surgery. J Cardiovasc Surg 35:185, 1994.
27. Royston D: High-dose aprotinin therapy: A review of the first five years' experience. J Cardiothorac Vasc Anesth 6:76, 1992.
28. Dietrich W, Barankay A, Hahnel C, Richter JA: High-dose aprotinin in cardiac surgery: Three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 6:324, 1992.
29. Royston D, Bidstrup BP, Taylor KM, Sapsford RN: Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2:1289, 1987.
30. Bidstrup B, Royston D, McGuiness C, Sapsford R: Aprotinin in aspirin-pretreated patients. Perfusion 5:77, 1990.
31. Cardinale V: 1996 "Red Book: Pharmacy's Fundamental Reference." Montvale, NJ: Medical Economics Data, 1996.
32. Trinh-Duc P, Wintrebert P, Boulfroy D, Albat B, Thevenet A, Roquefeuil B: Efficacy of ε-aminocaproic acid versus high dose aprotinin on intra and postoperative blood loss in cardiac surgery. Ann Chir 46:677, 1992.
33. Cousin MT, Boughenou F, Madi-Jebara S, Massonnet-Vastel S, Benmosbah L: Emploi des antifibrinolytiques en chirurgie cardiaque. Cah Anesthesiol 41:473, 1993.
34. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P: Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 108:1083, 1994.
35. Boughenou F, Madi-Jebara S, Massonnet-Castel S, Benmosbah L, Carpentier A, Cousin MT: Antifibrinolytiques et prevention du saignement en chirurgie cardiaque valvulaire. Arch Mal Coeur Vaiss 88:363, 1995.
36. Speekenbrink RGH, Vonk ABA, Wildevuur CRH, Eijsman L: Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary artery bypass grafting. Ann Thorac Surg 59:438, 1995.
37. Pugh SC, Wielogorski AK: A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 9:240, 1995.
38. Penta de Peppo A, Danilo Pierri M, Scafuri A, De Paulis R, Colantuono G, Caprara E, Tomai F, Chiariello L: Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery: Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J 22:231, 1995.
39. Menichetti A, Tritapepe L, Ruvolo G, Speziale G, Cogliati A, Giovanni CD, Pacilli M, Criniti A: Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: Aprotinin vs. tranexamic acid vs. epsilon aminocaproic acid. J Cardiovasc Surg 37:401, 1996.
40. Fremes SE, Wong BI, Lee E, Mai R, Christakis GT, McLean RF, Goldman BS, Naylor CD: Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 58:1580, 1994.
41. Dentz ME, Slaughter TF, Mark JB: Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. Anesthesiology 82:583, 1995.
42. Bohrer H, Fleischer F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth 4:222, 1990.
43. Cosgrove DM III, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, McCarthy PM, Loop FD: Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 54:1031, 1992.
44. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM: Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 105:147, 1993.
45. Lemmer J, Stanford W, Bonney S, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, Schaff HV, Tatooles CJ, Rumberger JA: Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 107:543, 1994.
46. Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H, Wolner E: Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 107:807, 1994.
47. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA: Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients underoing open-heart surgery. Anesthesiology 83:679, 1995.
48. Dietrich W, Jochum M: Effect of celite and kaolin on activated clotting time in the presence of aprotinin: Activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 109:177, 1995.
49. Sundt TM III, Kouchoukos MD, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ: Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 55:1418, 1993.
50. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P: Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary by-pass. J Thorac Cardiovasc Surg 101:958, 1991.
51. Pfannschmidt J, Steeg D, Jugert F: Routine intraoperative application of high-dose aprotinin in open heart surgery in adults: Antibody formation after first exposure. Curr Med Res Opin 13:282, 1995.
52. Dietrich W, Spath P, Ebell A, Richter JA: Prevalence of anaphylactic reactions to aprotinin: Analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 113:194, 1997.
53. Diefenbach C, Abel M, Limpers B, Lynch J, Ruskowski H, Jugert FK, Buzello W: Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. Anesth Analg 80:830, 1995.
54. Freeman JG, Turner GA, Venables CW, Latner AL: Serial use of aprotinin and incidence of allergic reactions. Curr Med Res Opin 8: 559, 1983.
55. Yanagihara Y, Shida T: Immunological studies on patients who received aprotinin therapy. Jpn J Allergol 34:899, 1985.
56. Schulze K, Graeter T, Schaps D, Hausen B: Severe anaphylactic shock due to repeated application of aprotinin in patients following intrathoracic aortic replacement. Eur J Cardiothorac Surg 7:495, 1993.